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Abstract
Bovine tuberculosis has been assessed according to the criteria of the Animal Health Law (AHL), in
particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of bovine
tuberculosis to be listed, Article 9 for the categorisation of bovine tuberculosis according to disease
prevention and control rules as in Annex IV and Article 8 on the list of animal species related to bovine
tuberculosis. The assessment has been performed following a methodology composed of information
collection and compilation, expert judgement on each criterion at individual and, if no consensus was
reached before, also at collective level. The output is composed of the categorical answer, and for the
questions where no consensus was reached, the different supporting views are reported. Details on
the methodology used for this assessment are explained in a separate opinion. According to the
assessment performed, bovine tuberculosis can be considered eligible to be listed for Union
intervention as laid down in Article 5(3) of the AHL. The disease would comply with the criteria as in
Sections 2, 3, 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and
control rules referred to in points (b), (c), (d) and (e) of Article 9(1). The main animal species to be
listed for bovine tuberculosis according to Article 8(3) criteria are several mammal species, as indicated
in the present opinion.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on bovine tuberculosis (bTB) according to
the criteria of the AHL articles as follows:
• Article 7: bovine tuberculosis proﬁle and impacts
• Article 5: eligibility of bovine tuberculosis to be listed
• Article 9: categorisation of bovine tuberculosis according to disease prevention and control
rules as in Annex IV
• Article 8: list of animal species related to bovine tuberculosis.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of bTB according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
The EFSA/ECDC Zoonoses report for 2015–2016 (EFSA and ECDC, 2016) states that ‘Bovine
tuberculosis is a zoonotic animal disease regulated by Council Directive 64/432/EEC1. According to
Directive 2003/99/EC2 on the monitoring of zoonoses and zoonotic agents, the zoonosis and zoonotic
agent to be included in monitoring of bovine tuberculosis is tuberculosis due to Mycobacterium bovis
(Annex I, A). Since 2003 in addition to M. bovis, Mycobacterium caprae has been recognised as a
distinct bacterial species and causative agent of bovine tuberculosis and of tuberculosis in humans and
animals other than cattle (Aranaz et al., 2003). Disease caused by M. caprae is not considered to be
substantially different from that caused by M. bovis, and the same tests can be used for its diagnosis
(OIE, 2015). In the meeting of 7 May 2013 of the Committee on the Food Chain and Animal Health
(Section Animal Health and Welfare), the European Commission circulated and presented a working
document (SANCO/7059/2013) on the subject matter (European Commission, 2013). Without prejudice
to the exclusive competence of the European Court of Justice to authoritatively interpret Union
legislation, the document concluded that all provisions explicitly referring to M. bovis in Council Directive
64/432/EEC should be understood as also applicable to M. caprae. Based on the above, a distinction is
1 Council Directive 64/432/EEC of 26 June 1964 on animal health problems affecting intra-Community trade in bovine animals
and swine. OJ 121, 29.7.1964, p. 1977–2012.
2 Directive 2003/99/EC of the European Parliament and of the Council of 17 November 2003 on the monitoring of zoonoses and
zoonotic agents, amending Council Decision 90/424/EEC and repealing Council Directive 92/117/EEC. OJ L 325, 12.12.2003,
p. 31–40.
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descriptively made for the ﬁrst time in the EU annual summary reports on trends and sources of
zoonoses, of reporting by MS on Mycobacterium tuberculosis complex, M. bovis and M. caprae’.
Therefore, for the purposes of this fact-sheet, the deﬁnition of bTB is ‘Infection in cattle with any of
the disease-causing mycobacterial species within the M. tuberculosis complex (MTC)’. This is consistent
with the EU Working Document on the Eradication of Bovine Tuberculosis in the European Union (EU)
that was accepted by the bTB subgroup of the Task Force on monitoring animal disease eradication,
i.e. it was drawn up by the Commission’s own tuberculosis (TB) task force which comprised experts on
bTB eradication from a variety of countries and a number of epidemiologists (European Commission,
2006).
Mycobacterium bovis is by far the most important causative agent of tuberculosis in livestock and
wildlife and in bovines is commonly referred to as bTB. However, tuberculosis in mammals, including
humans, can be caused by most of the members of the Mycobacterium tuberculosis complex (MTBC),
including M. bovis, M. tuberculosis, M. microti, M. africanum, M. canettii, M. caprae, M. pinnipedii,
M. orygis, M. mungi and the dassie bacillus (Brosch et al., 2002; Michel et al., 2006). Still, unexplained
differences in susceptibility of different species to different members of the MTBC have been observed.
Aerosol exposure of cattle to M. bovis is considered the most frequent route of infection; gross lesions
usually involve the lungs and thoracic lymph nodes (Francis, 1958). Cattle exposed by ingestion of
food and water contaminated with M. bovis often develop primary foci in lymph tissue associated with
the intestinal tract (Thoen and Williams, 1994). Pathogenic mycobacteria produce granulomatous
lesions in tissues of a wide range of domestic and wild animal species and man causing a general state
of illness, coughing and eventual death. Bovine tuberculosis usually has a prolonged course, and
clinical signs take months or years to appear. The usual clinical signs include weakness, loss of
appetite, weight loss, ﬂuctuating fever, intermittent hacking cough, diarrhoea and large prominent
lymph nodes.
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
The use of the term bTB to refer to an M. bovis infection in species other than bovines creates the
impression that bovines are the only species responsible for the spread of this organism, whereas
multiple species (domestic and wild) can maintain and spread the infection with M. bovis without an
ongoing association with cattle.
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Most mammalian species are susceptible to infection with M. bovis and other related members of
the MTBC that cause tuberculosis (O’Reilly and Daborn, 1995; Brosch et al., 2002; Delahay et al.,
2002, 2007; Aranaz et al., 2004). In Europe, major susceptible species include badgers (Murhead and
Burns, 1974; Barrow and Gallagher, 1981; Little et al., 1982a,b; Caffrey, 1994) red, roe and fallow
deer (Clifton-Hadley and Wilesmith, 1991; Bode, 1995; Delahay et al., 2002, 2007; Parra et al., 2006;
OIE, 2007), wild boar (Sus scrofa) and feral pig (Di Marco et al., 2008). Isolation of M. bovis from wild
boar is commonplace in Europe (Biolatti et al., 1992; Schultz et al., 1992; Aranaz et al., 1996; Serraino
et al., 1999; Pavlik et al., 2002; Machackova et al., 2003; Duarte et al., 2008; Gortazar et al., 2008;
Wilson et al., 2009). Also susceptible are red fox (Martın-Atance et al., 2005; Delahay et al., 2007),
mink (Delahay et al., 2002), ferret (Delahay et al., 2002), stoats (Delahay et al., 2007), rats (Delahay
et al., 2002), ﬁeld vole (Delahay et al., 2002), moles (Delahay et al., 2007), squirrels (Delahay et al.,
2007), otters (Stephens, 1957) and Iberian lynx (Briones et al., 2000). M. bovis or other members of
the M. tuberculosis-complex have been also isolated from camels, antelope, primates, llamas, kudu,
eland, tapir, elk, elephants, sitatunga, oryx, addax, rhinoceros, possums, seals, hares, rabbits,
raccoons, coyotes and several predatory felines including lions, tigers, leopards and lynx (O’Reilly and
Daborn, 1995; de Lisle et al., 2001; Michel et al., 2006).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
Although cattle are thought to be the true host of M. bovis, a wide range of domestic species can
be infected (Cousins, 2001). Isolations have been made from buffalo, bison, goats, camelids (including
alpaca, llama, camels), pigs, deer, antelopes, dogs and cats (EFSA and ECDC, 2013). It rarely affects
equids or sheep. However, in Spain and elsewhere, several outbreaks in sheep have been reported
recently, all of which had epidemiological links with TB-infected cattle herds or have occurred in
endemic areas (Malone et al., 2003; van der Burgt et al., 2013; Mu~noz-Mendoza et al., 2016).
AHL assessment on bovine tuberculosis
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Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Badgers (Corner et al., 2007, 2008; Lesellier et al., 2009), deer (Grifﬁn et al., 1999; Palmer et al., 2002),
wild boar (Garrido et al., 2011), rabbits (Arrazuria et al., 2017), ferrets (Qureshi et al., 1999; Cross et al.,
2000) and possums (Ramsey et al., 2009; Tompkins et al., 2009). Little is known about the susceptibility of
birds to M. bovis although they are generally thought to be resistant. Experimental infections have recently
been reported in pigeons after oral and intratracheal inoculation (Fitzgerald et al., 2003).
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Most domestic mammalian species are susceptible to experimental infection. The most developed
experimental models of infection of livestock are: cattle (Dean et al., 2005; Buddle et al., 2016), camelids
(Stevens et al., 1998), pigs (Bolin et al., 1997), goats (de Val Perez et al., 2011; Gonzalez-Juarrero et al.,
2013), and deer (Palmer et al., 1999).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
• Badgers (Meles meles) (Clifton-Hadley et al., 1995; Grifﬁn et al., 2005; Donnelly et al., 2006;
McDonald et al., 2016).
• Wild boar (Sus scrofa) (Gortazar et al., 2005; Parra et al., 2006; Naranjo et al., 2008).
• Deer (Aranaz et al., 2004; Delahay et al., 2007; Zanella et al., 2008).
Parameter 6 – Domestic reservoir species (or family/orders)
Cattle, sheep, goats, camelids (especially alpaca and llama), buffalo and bison.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
Livestock: EFSA and ECDC (2016) presented an overview of the M. bovis infection in Europe as
below.
The 2015 list of countries and regions ofﬁcially tuberculosis free3 (OTF) was: Austria, Belgium, the
Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, seven regions and 14
provinces in Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, all administrative regions
within the superior administrative unit of the Algarve in Portugal, Poland, Slovakia, Slovenia, Sweden,
Scotland and the Isle of Man in the United Kingdom, Norway and Switzerland, in accordance with EU
legislation (Commission Implementing Decision 2014/91/EU4). Liechtenstein has the same status (OTF)
as Switzerland. In Iceland, which has no special agreement concerning animal health status with the
EU, the last outbreak of bTB was reported in 1959.
Bulgaria, Croatia, Cyprus, Greece, Ireland, Italy, Portugal, Romania, Spain and the United Kingdom
had not yet achieved the country-level OTF status in 2015. The Umbria Region in Italy has been added
to the OTF Regions in 2017 (Commission Implementing Decision (EU) 2017/8885.)
The overall proportion of cattle herds infected with, or positive for, bTB, considering all the EU
regions, is 0.7% of the cattle herds in the EU, although there is a heterogeneous distribution of bTB in
3 As laid down in Annex A.I of Directive 64/432/EEC, a Member State or region of a Member State may be declared ofﬁcially
tuberculosis-free if the percentage of bovine herds conﬁrmed as infected with tuberculosis has not exceeded 0.1% per year of all
herds for six consecutive years and at least 99.9% of herds have achieved OTF status each year for six consecutive years; each
bovine animal is identiﬁed in accordance with Community legislation; all bovine animals slaughtered are subjected to an ofﬁcial
post-mortem examination; the procedures for suspension and withdrawal of ofﬁcially tuberculosis-free status are complied with.
4 2014/91/EU: Commission Implementing Decision of 14 February 2014 amending Annex II to Decision 93/52/EEC as regards
the recognition of certain regions of Italy and Spain as ofﬁcially free of brucellosis (B. melitensis) and amending Annexes I, II
and III to Decision 2003/467/EC as regards the declaration of Hungary as ofﬁcially tuberculosis-free, Romania and certain
regions of Italy as ofﬁcially brucellosis-free, and certain regions of Italy as ofﬁcially enzootic-bovine-leukosis-free. OJ L 46,
18.2.2014, p. 12–17.
5 Commission Implementing Decision (EU) 2017/888 of 22 May 2017 amending Decision 2003/467/EC as regards the ofﬁcial
tuberculosis-free status of the region of Umbria of Italy and of the enzootic-bovine-leukosis-free status of Poland, amending
Decision 2004/558/EC as regards the infectious bovine rhinotracheitis-free status of Germany, and amending Decision 2008/
185/EC as regards the Aujeszky’s disease-free status of certain regions of Poland and the approval of the eradication
programme for Aujeszky’s disease for the region of Veneto of Italy. OJ L 135, 24.5.2017, p. 27–34.
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Europe with a pronounced spatial clustering. The prevalence ranges from absence of infected animals
in most OTF regions to a regional prevalence in non-OTF regions of 15.8% in Andalusia, Spain,
considering all herds, or a reported regional prevalence of test-positive cattle herds of 17.7% within
the United Kingdom in Wales and England (Figure 1).
In the 18 OTF, Member States (MSs) and in the regions declared OTF in the three non-OTF MSs,
Italy, Portugal and the United Kingdom, which represent a total population of 1,314,645 cattle herds,
annual surveillance programmes are carried out to conﬁrm freedom from bTB. Their reporting
requirements are, among other indicators, the number of infected herds and the total number of herds
existing. Eight of these MSs reported a total of 155 bTB-infected herds from these areas; six MSs
reported infection with M. bovis (Belgium, 3 herds; Germany, 12; Italy, 3; Poland, 28; Slovenia, 1; and
the United Kingdom, 2), whereas Austria reported four herds infected with M. caprae and France
declared 102 herds infected with M. tuberculosis-complex. The prevalence of bTB-infected herds in
these OTF regions of 21 MSs in 2015 was 0.012%, compared to 0.011% during 2014 in the OTF
regions of 19 MSs. From 2010 to 2015, the number of cattle herds reported infected in the OTF
regions of the EU per year was 227, 200, 209, 197, 139 and 155, respectively.
Bovine TB was not detected in 2015 in the non-MSs Iceland, Norway, Switzerland and
Liechtenstein.
In 2015, there were a total of 1,167,945 cattle herds in the non-OTF regions of the 10 MSs with
non-OTF status. The number of infected herds reported was 21 in Croatia (53 in 2014), 4,002 in
Ireland (4,293 in 2014), 433 in Italy (380 in 2014), 94 in Portugal (108 in 2014), 3,070 in Spain (1,867
during 2014) and 9,628 in the United Kingdom (10,172 in 2014). The reports concerned M. bovis
(Ireland, Italy, Portugal and the United Kingdom) or Mycobacterium tuberculosis complex (Croatia and
Spain). As in 2014, Cyprus did not report any infected herds for the year 2015, whereas Bulgaria
reported six (10 in 2014) and Greece 187 (203 in 2014) M. bovis-infected herds. Romania reported 36
M. caprae-infected herds (36 also in 2014).
Figure 1: Proportion of cattle herds infected with or positive for bovine tuberculosis in 2015 (from
EFSA and ECDC (2016))
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From 2010 to 2015, the total number of test-positive cattle herds in these EU non-OTF regions
remained at the same level and 17,814; 17,102; 18,208; 18,059; 17,122; and 17,441 were reported
from 2010 to 2015, respectively. The overall prevalence of that period is increasing from 1.05% to
1.49% in 2015. Concomitantly, the total number of cattle herds decreased importantly from 1,638,694
in 2010 to 1,167,945 in 2015.
A herd prevalence > 10–20% is reported by the United Kingdom in Wales and England, with a
reported highest regional prevalence in the EU of 17.7%. When considering all herds, the regional
prevalence was 12.0%. For Northern Ireland, a low prevalence (> 1–10%) of test-positive herds was
reported, but with a slightly increasing trend. Also, Ireland and Spain reported a low prevalence with a
decreasing (Ireland) and a slightly increasing trend (Spain) in recent years. When considering all
herds, Spain reported a regional prevalence of 15.8% in Andalusia. Italy and Portugal reported
prevalences > 0.1–1% in their remaining non-OTF regions.
Greece reported a very low prevalence of infected cattle herds (M. bovis) with a slightly increasing
trend from 0.44% in 2006 to 0.85% in 2015.
In 2015, 12 MSs and two non-MSs investigated M. bovis in other animals and it was reported in
2,375 animals: water buffalos (1,343), wild boar (398), badgers (311), deer (195), alpacas (35), cats
(34), zoo animals (21), pigs (20), foxes (8), sheep (8) and lamas (2). Thirteen MSs and two non-MSs
investigated animals for Mycobacterium species other than M. bovis. M. tuberculosis-complex was
reported not only in cattle, but also from wild alpacas (4), goats (4,022), cat (1), sheep (2), wild boars
(31 slaughter batches), wild deer (45) and zoo animals (4), among which elephants. M. caprae was
reported, in addition to the M. caprae-positive herds in Austria and in Romania (see above), in 177
animals by three MSs (Germany, Hungary and Spain): cattle (169), wild boar (5), wild deer (2), and a
fox.
Wildlife Badgers: The prevalence of infection in road-killed or culled badgers is of the order of
10–15% in GB, but locally it can vary between a few percent and 50%. The UK government conducted
the Randomised Badger Culling Trial (RBCT), a large-scale ﬁeld experiment to assess the effects of
badger culling on bTB incidence in cattle. As part of this study, badgers were removed from ten
100 km2 bTB hotspot areas. The prevalence of bTB in badgers in these areas, as determined by
microbiological culture of tissue following post-mortem examination (PME), showed considerable
variation among areas, with values ranging from 2% to 37% (Bourne et al., 2007; Jenkins et al.,
2008). These are likely to be underestimates of true prevalence given the limited sensitivity (55%) of
standard post mortem and culture detection relative to extended post-mortem and culture (Crawshaw
et al., 2008). In a similar study in the RoI, the prevalence of bTB in badgers in four large removal
areas was 19.5% (Grifﬁn et al., 2005). During a 22-year period of a long-term study of a wild badger
population in a bTB hotspot area in south west England, annual bTB prevalence ranged from 1% to
11%, although this was based on the less sensitive approach of microbiological culture of clinical
samples (i.e. faeces, urine, sputum, wound and abscess swabs) from live badgers (Delahay et al.,
2000; Vicente et al., 2007).
Wild boar: M. bovis infection in Eurasian wild boar is widespread in Europe, being reported in
both OTF and non-OTF countries. In the last 10 years, reports of conﬁrmed infection based on more
than 20 animals have originated from Croatia, France, Italy, Portugal, Slovakia and Spain. Prevalence
ﬁgures range from 1% to 63%. Most reports came from Mediterranean countries and the highest
prevalence was recorded in the southern part of the Iberian Peninsula (Wilson et al., 2009; Vicente
et al., 2013).
Deer: M. bovis infection in wild deer (mostly fallow and red) is widespread in Europe, and has
been reported in both OTF and non-OTF countries. In the last 10 years, reports of conﬁrmed infection
based on more than 20 animals have originated from the United Kingdom, Spain and Ireland. From
the limited number of reports, it is clear that infection is highly clustered within certain localities. In red
deer, prevalence estimates, again based on 20 or more animals, range from 1% to 27%; in roe deer,
from 0% to 3%; in fallow deer, from 3% to 21%; in muntjac there was a single estimate of 5%; and
in sika and sika crosses another single estimate of 4% (Wilson et al., 2009).
In carnivores, such as the fox, domestic cat and Iberian lynx, prevalence estimates based on 20
or more animals range from 1% to 17%; similarly, in mustelids (excluding badgers) from 1% to 4%; in
rodents, from 1% to 3%; in insectivores (the mole), 1%; in herbivores (the chamois), less than 1%
(Wilson et al., 2009).
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Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
Figures on TB morbidity in cattle are rarely presented as such and therefore must be inferred or
extrapolated from the data available from countries where reactor animals are not culled. Where
eradication programmes are in place, animals that fail to thrive are eventually culled from herds. Some
of these animals will be found to be infected, exhibiting TB lesions at slaughter. Exceptions to this
practice include Nepal and India where for cultural and religious reasons even reactor cattle are not
culled. A mycobacteriological examination of milk and faeces from cattle and water buffalo positive on
the cervical single intradermal test in Nepal isolated 13 M. bovis strains from 17% of buffaloes and
16% of cattle and in the Kerala state in India 60% of cattle were partially or completely affected by
the disease and all crossbred cattle were suffering from tuberculosis. In Ireland, for example in the
early 1950s before the bovine TB eradication programme commenced, there were approximately
4.5 million cattle of which some 17% were tuberculous (cows 22%, other cattle 8%) (Good, 2006). In
Great Britain, prior to and in the early stage of TB eradication in bovines, Francis (1948) quotes the
frequency of TB present in the udder and milk as 0.5–19.5% of tuberculous cows and 5–31% in cows
with generalised tuberculosis (Francis, 1948). Analysis of milk in countries with no bTB eradication
programme continues to show similar levels of M. bovis detection (Jha et al., 2007; Srivastava et al.,
2008). In Argentina in the period 1969–2011, the percentage of animals that suffered total or partial
condemnation at slaughter caused by TB lesions decreased from 6.7% to 0.6% as tuberculin testing of
live cattle reduced TB incidence; in Chile the detection of TB in slaughtered cattle increased from 33 to
190 cases per 10,000 slaughtered animals between 1996 and 2005 and in 2011 was estimated to be
100 cases per 10,000 with 31.4% of tuberculous carcases condemned for generalised TB (Thoen
et al., 2014).
In countries with control programmes, TB in cattle is often conﬁned to one or two animals in a
herd, although explosive outbreaks may occur especially if calves have been fed with contaminated
milk. Nowadays in EU countries M. bovis infection rarely presents a clinical disease and it normally
appears as apparently healthy animals reacting to the diagnostic tests. The severity of the disease
varies with the dose of infectious organisms and individual immunity. Infected animals may remain
asymptomatic, become ill only after stress or in old age, or develop a chronic, debilitating fatal
disease. In developed countries, most reactors are detected during routine testing and mortality from
tuberculosis is rare. In developing countries where there are no test and cull control programmes in
place, overall prevalence and herd prevalence may be much higher (e.g. ca. 50% herd prevalence has
been reported for Ethiopia (Firdessa et al., 2012; Dejene et al., 2016). This is akin to the situation
described in GB in the 1940s where incidence was reported to increase 7% for each year of life
reaching 40% after 5–6 years in dairy cattle (Francis, 1948).
In maintenance hosts, other than cattle, the prevalence of infection and the severity of the disease
vary with species (Wilson et al., 2009).
Mortality
Parameter 3 – Case-fatality rate
Cattle: Nowadays in EU countries, M. bovis infection rarely presents as clinical disease and it
normally appears as apparently healthy animals reacting to the diagnostic tests, or they become ill
only after stress or in old age, or develop a chronic, debilitating fatal disease, whose rate is not
available. Moreover animals that fail to thrive are eventually culled from herds and they could be found
to be affected and exhibiting TB lesions at slaughter. Therefore, case-fatality rates due to TB in cattle
are unavailable.
Wildlife: It is difﬁcult to assess mortality due to M. bovis infection in wildlife populations. However,
the following estimations have been reported.
Badgers: There is evidence for early onset of disease-induced mortality in male but not female
badgers. Males also have higher risk of infection and more rapid disease progression (Graham et al.,
2013). In a long-term study of a natural population of badgers to the nearest month, male average life
expectancies were estimated to be 32 months for uninfected badgers and 22 months for infected
badgers. Female average life expectancies were found to be 40 months for uninfected badgers and
35 months for infected badgers. When they are uninfected, this equates to males having on average a
20% lower life expectancy compared with females, with the acquisition of infection increasing this
difference to 37% (McDonald et al., 2014).
Wild boar: A recent study of two different populations of wild boar with endemic tuberculosis in
Spain suggested that tuberculosis accounted for 30% of total deaths (Barasona et al., 2016).
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3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
The conﬁrmed cases of tuberculosis due to M. bovis in humans were 157 in 2011 reported by 12
EU MSs, Norway and Switzerland (EFSA and ECDC, 2013), 136 in 2012 by 9 EU MSs, Norway and
Switzerland (EFSA and ECDC, 2014), 141 in 2013 by 9 EU MSs and Switzerland (EFSA and ECDC,
2015a), 145 in 2014 by 9 EU MSs, Norway and Switzerland (EFSA and ECDC, 2015b), and 170 in
2015, reported by 26 EU MSs, Norway and Switzerland (EFSA and ECDC, 2016). The EU notiﬁcation
rate was stable between 2011 and 2015 (0.03 cases per 100,000 population), and there was no
association between a country’s status as OTF and notiﬁcation rates in humans for the years 2013,
2014 and 2015. M. bovis infection and probably also M. caprae may also be transmitted human to
human and thus each M. bovis/M. caprae case may not deﬁnitively be zoonotic in origin (Evans et al.,
2007; Sunder et al., 2009; Buss et al., 2016).
As tuberculosis is a chronic disease with a long incubation period, it is not possible to assess
travel-associated cases in the same way as diseases with acute onset. Instead, the distinction is made
between individuals with the disease born in the reporting country (native infection) and those moving
there at a later stage (foreign infection). In a few cases, the distinction is also made based on the
nationality of the cases. From 2011 to 2015, among cases with known origin, there were a larger
proportion of native cases in countries non-OTF than in countries that were OTF. However, for the
years 2013, 2014 and 2015, there was no clear association between a country’s status as OTF and
notiﬁcation rates in humans.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
The mycobacteria are susceptible to antibiotics, although M. bovis is intrinsically resistant to
pyrazinamide. Infected animals are generally slaughtered and are not treated. Treatment requires
prolonged use of multiple drugs, the administration of which can be very difﬁcult to achieve. This risks
dosage not being met and a risk of developing antibiotic resistant strains of bacteria, which is a
concern for both animal and human health. Inadequate dosage may result in the animal remaining
infected often without signs of disease. Thus, antibiotic treatment is rarely attempted because of the
high cost, lengthy treatment time, risk of antibiotic resistance and the larger goal of eliminating the
disease. In some countries it may be illegal. Few cases of acquired antimicrobial resistance are
described in the literature on M. bovis or M. caprae isolated from human cases (Armstrong and
Christie, 1998; McLaughlin et al., 2012) and these may have been a result of selection of resistance
due to treatment of humans infected with M. bovis (Guerrero et al., 1997).
3.1.1.5. The persistence of the disease in an animal population or the environment
Animal population
Parameter 1 – Duration of infectious period in animals
Bovine TB, caused by M. bovis, is a chronic, primarily respiratory disease that can take a variable
amount of time (from a few weeks to a lifetime) to develop from infection to clinical disease and to
become infectious to other animals. The transmission rate between animals is low and the epidemic
only progresses slowly. Animals infected with MTC tend to shed M. bovis intermittently in relatively low
numbers of organisms (compared to acutely infectious and contagious viral diseases such as foot and
mouth disease).
Parameter 2 – Presence and duration of latent infection period
After initial infection, the mycobacteria may lie dormant in the body, sometimes without
multiplication or producing any visible lesions in tissues for variable amounts of time. Recent modelling
has estimated that in a European setting the latent period is between 2 and 8 months (Bekara et al.,
2014); however, latent infection may last a lifetime and latency of variable duration is only detected at
slaughter (Clegg et al., 2016).
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Parameter 3 – Presence and duration of the pathogen in healthy carriers
The symptoms of bTB usually take months to develop. Infections can also remain dormant for
years and reactivate during periods of stress or in old age. Thus, the pathogen may persist for a
lifetime in latently infected animals.
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
M. bovis can survive for several months in the environment, particularly in cold dark and moist
conditions (Williams and Hoy, 1930). M. bovis bacilli can survive for up to approximately 400 days in
running water (Briscoe, 1912) and water dilution will reduce the population of M. bovis organisms. In
a recent study, M. bovis persisted up to 88 days in soil, 58 days in water and hay, and 43 days on
corn under experimental conditions (Fine et al., 2011). Persistence of M. bovis in the environment was
signiﬁcantly shorter in the spring/summer season, characterised by the highest average daily
temperatures and increased exposure to sunlight over the 12-month period.
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Natural transmission can occur between domestic and wild animals. Cattle-to-cattle transmission of
organisms of the MTBC occurs mainly by the respiratory route through the inhalation of aerosols
containing the bacteria when the animals are in close contact. Oral route of infection due to the
ingestion of mycobacteria from the environment cannot be discounted in some cases since it has been
also described and vertical transmission is possible. Sources of M. bovis for animals include feed or
water contaminated with urine, faeces or exudates from an infected animal (Shefﬁeld et al., 1997;
Hirsh and Zee, 1999; Thoen et al., 2008). Contaminated running water was recognised in the ﬁrst half
of the twentieth century as a mean of transmitting the disease (Garner, 1946) as M. bovis survives in
water and may enter the respiratory tract during drinking (Phillips et al., 2003). Common use of
natural water sources by cattle and wildlife could also transmit the disease (Phillips et al., 2002).
M. bovis may survive for some time in the environment (Kukielka et al., 2013; Santos et al., 2015).
This observation is key to understanding the indirect transmission and maintenance of infection in
complex environments, involving multiple host species. In Mediterranean areas with a high prevalence
of TB, it is common to detect MTC DNA in mud and water samples (Santos et al., 2015; Barasona
et al., 2016). Direct contact inter species is rare (0.38% of all interactions (Cowie et al., 2016)).
Therefore, transmission between species of MTC depends mainly on indirect contacts. Especially in
Mediterranean environments, there is a high risk of these contacts at waterholes and other water
points during the dry season (Barasona et al., 2014a,b). The evaluation of the MTBC hazard posed to
cattle from wildlife across Europe demonstrated that cattle pose the greatest current and potential
MTBC hazard for the majority of countries. The most common host communities for MTBC hazard in
Europe are cattle-deer-wild boar systems, which were found in 15 countries across Europe. Wild boar
poses the greatest hazard of all the wildlife species, indicating that wild boar have the greatest ability
to transmit disease to cattle (Hardstaff et al., 2014). This is of particular concern given current
population and distribution increases of some susceptible wildlife species, especially wild boar and deer
which can help to spread pathogens to new areas and the paucity of wildlife MTBC surveillance
programmes. In countries and regions with high wild boar populations in particular, there are likely to
be signiﬁcant advantages to MTBC control from developing integrated MTBC surveillance schemes
incorporating both cattle and wild boar. In the UK and Ireland, the Eurasian badger (Meles meles) acts
as a signiﬁcant reservoir of infection for cattle. In areas such as south-west England, where bTB
breakdowns are common in the cattle population and the disease is endemic in local badgers,
molecular studies show that both cattle and badgers are infected with identical strains of M. bovis,
consistent with transmission of this infection between the two species (Hardstaff et al., 2014).
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Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
The most important way that people can become infected is by the consumption of unpasteurised
milk or dairy products from infected cows and where bTB is poorly controlled in livestock and
consumption of raw milk or unpasteurised dairy products is frequent, bTB may represent an important
human health risk. This was an important cause of childhood tuberculosis until pasteurisation became
widespread. As mycobacteria survive readily in water, this has been identiﬁed as one of the major
sources of human non-tuberculous mycobacterioses (Dailloux et al., 1999). Occasional cases may
occur through the consumption of other products accidentally contaminated with the organism.
Infection through consumption of contaminated meat is thought to be very rare or non-existent in
Europe. Inhalation of the organism is signiﬁcant for people working with infected animals but is not
usually important for the general public. Human to human transmission is rare but has been seen in
exceptional circumstances especially in immunocompromised individuals (de la Rua-Domenech, 2006;
Evans et al., 2007). However, while immunocompromised individuals are particularly susceptible to all
types of MTBC, human to human spread of M. bovis is not always conﬁned to immune-compromised
individuals. When humans are actively infected with pulmonary MTBC due to M. bovis transmission
may be as common as it is with other causes of MTBC since the majority of MTBC infected persons are
not actually infectious at all stages of infection (Evans et al., 2007; Sunder et al., 2009; Buss et al.,
2016).
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
M. bovis infection is spread to cattle primarily through the inhalation of infectious aerosols, either
from a coughing or sneezing animal with open tuberculosis or from infected dust particles. Given the
predominance of aerosol transmission, infection is spread more rapidly in intensive animal husbandry
situations than in extensive or rangeland conditions. Aerosol transmission is effective only over short
distances (1–2 m) and hence cattle density is a signiﬁcant factor in the rate of transmission.
Consequently, on dairy farms with a high density of cattle, or in production systems which house
animals together for extended periods, the transmission rate between susceptible animals may be very
high. In stables and barns used to house tuberculous cattle, infected droplets and particles may be
constantly present in the air, presenting a hazard to susceptible animals and farm workers (Cousins,
2001).
Bekara et al. (2014) reported that the median within-herd transmission coefﬁcient for housed
animals in France was ﬁve times as high as in the pasture: 0.43 month1 (0.16–0.84) and
0.08 month1 (0.01–0.32), respectively. These estimated medians were consistent with the estimates
of within-herd transmission of bTB in Spain proposed by Alvarez et al. (2012b), with higher
transmission coefﬁcients in dairy herds (median 0.39 month1) than in beef herds (0.19 month1).
These estimated values of the transmission coefﬁcients are also in the same range as values obtained
by other studies: 0.22 month1 in the study of Barlow et al. (1997) in New Zealand and
0.18 months1.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
Estimates for Great Britain suggest that R0 in High-Risk Areas for bTB range from 1.3 to 1.9 and in
Low-Risk Areas for bTB the R0 may range from 0.6 to 1.4 (O’Hare et al., 2014). Estimates for
between-herd R0 for bovine tuberculosis in Great Britain have been derived from a strategic model of
the interaction between M. bovis, cattle and badgers, and lie in the interval 1.02–1.11 (Cox et al.,
2005; Godfray et al., 2013). However, herd size may also affect rate of spread (the larger the herd the
higher the potential R0) as will the presence of ‘super-shedder’ animals. In the absence of a control
program and once bTB has become enzootic within a herd, the median effective reproductive ratio
was estimated to be 2.2 in beef herds and 1.7 in dairy herds. This difference was due to a lower age
at culling for dairy cows than for beef cows. These low estimates were consistent with ﬁeld
observations of a low prevalence level in French bTB-infected herds (Bekara et al., 2014).
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3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
See Figure 1.
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
For the OTF, MSs and the regions declared OTF in the non-OTF MSs, from 2010 to 2015, the
number of cattle herds per year, the number of cattle herds reported infected per year and the
prevalence of bTB-infected herds per year are displayed in Figure 2.
Figure 3 displays the MS-speciﬁc trends of the prevalence of bTB test-positive cattle herds in the
non-OTF regions of six MSs with the EU co-ﬁnanced eradication programmes, during 2004–2015.
Greece, a non-OTF MS without an EU co-ﬁnanced eradication programme, reported a very low
prevalence of infected cattle herds (M. bovis) with a slightly increasing trend from 0.44% in 2006 to
0.85% in 2015.
OTF: Ofﬁcially bovine tuberculosis free in cattle.
Figure 2: Proportion of cattle herds infected with or positive for bovine tuberculosis, in OTF regions,
EU, 2010–2015 (EFSA and ECDC, 2016)
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Risk of introduction
Parameter 3 – Routes of possible introduction
Bovine tuberculosis is already present in a number of MSs.
Parameter 4 – Number of animal moving and/or shipment size
Bovine tuberculosis is already present in a number of MSs.
Parameter 5 – Duration of infectious period in animal and/or commodity
Due to the chronic nature of infection and associated variable latency period, the infectious period
can last for the lifetime of an infected animal.
Parameter 6 – List of control measures at border (testing, quarantine, etc.)
Import controls – The rules governing control measures at borders are laid down in Council
Directive 91/496/EEC6, consolidated version, which foresees veterinary checks on all live animals
entering the Community from third countries. Import conditions for bovine animals are regulated in
Council Directive 2004/68/EC7 and more speciﬁcally in Commission Regulation (EU) No 206/20108,
where it is speciﬁed that ungulates can be introduced into the Union if they come from a third
countries or territories for which there is a model veterinary certiﬁcate (Annex I) and if they are
Figure 3: Prevalence of bovine tuberculosis test-positive cattle herds, in non-OTF regions of six
non-OTF coﬁnanced Member States, 2004–2015 (EFSA and ECDC, 2016)
6 Council Directive 91/496/EEC of 15 July 1991 laying down the principles governing the organization of veterinary checks
on animals entering the Community from third countries and amending Directives 89/662/EEC, 90/425/EEC and 90/675/EEC.
OJ L 268, 24.9.1991, p. 56–68.
7 Council Directive 2004/68/EC of 26 April 2004 laying down animal health rules for the importation into and transit through the
Community of certain live ungulate animals, amending Directives 90/426/EEC and 92/65/EEC and repealing Directive 72/462/EEC.
OJ L 139, 30.4.2004, p. 321–360.
8 Commission Regulation (EU) No 206/2010 of 12 March 2010 laying down lists of third countries, territories or parts thereof
authorised for the introduction into the European Union of certain animals and fresh meat and the veterinary certiﬁcation
requirements. OJ L 73, 20.3.2010, p. 1–121.
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accompanied by the veterinary certiﬁcate and they comply with the requirements set out in the
certiﬁcate.
Parameter 7 – Presence and duration of latent infection and/or carrier status
After initial infection, the mycobacteria may lie dormant in the body, sometimes without
multiplication or producing any visible lesions in tissues for variable amounts of time. Recent modelling
has estimated that in a European setting the latent period is between 2 and 8 months (Bekara et al.,
2014). However, the latent period may last for the lifetime of an infected animal.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
According to Council Directive 64/432/ECC, the available diagnostic tools for bTB are:
• The in vivo single and comparative intradermal tuberculin (SIT and SCIT, respectively) tests as
the ofﬁcial diagnostic assays for bTB in the MSs. The test details are described in the Directive.
• The in vitro interferon-gamma (IFN-c), referred to in the OIE (2015). This test is considered an
ancillary assay to the tuberculin test (Council Directive 64/432/EEC, amended by Commission
Regulation (EC) No 1226/20029), and may be authorised by MSs to maximise detection of
infected and diseased cattle in a herd or in a region. When used in combination with skin
tests, overall test sensitivity is increased.
Although the IDEXX serological test is OIE certiﬁed, it is not approved by the EU as a test eligible
for co-funding under currently co-funding rules because it is not speciﬁcally listed in the Directive.
Further, the performance of this test has not been examined by the EU.
In animals slaughtered as test negative and showing lesions suggestive of TB, tissues are taken
and conﬁrmation of infection is by culture or through microscopic histological examination of post
mortem material. Polymerase chain reaction (PCR) is also being used increasingly because it allows a
more rapid diagnosis.
Monitoring for lesions consistent with tuberculosis by post-mortem examination of cattle carcasses
at abattoirs is also a critical element of tuberculosis eradication. However, meat inspection procedures
are estimated to detect only 50% of cattle with tuberculous lesions, compared with a detailed
necropsy procedure that included slicing lymph nodes in a laboratory at 2 mm intervals and visual
examination of the cut surfaces (85%) (Corner et al., 1990).
The available diagnostic tests are described in the OIE Manual of Diagnostic Tests and Vaccines for
Terrestrial Animals (OIE, 2015).
Control tools
Parameter 2 – Existence of control tools
The EU has a set of speciﬁc legislation for a number of animal diseases depending on their
potential social and economic impact. This includes notiﬁcation obligations, diagnostic methods,
measures to be applied in case of suspicion and conﬁrmation of disease and, where applicable,
regionalisation measures.
The most relevant legislation regarding eradication of bovine TB is summarised in Council Directive
77/391/EEC10 which introduced Community measures for the eradication of TB in cattle. In this
Directive, MSs are obliged to draw up programmes for accelerated eradication (ﬁnancial contribution
Community), amended and completed by Council Directives 78/52/EEC, 82/400/EEC11 and Council
Decision 87/58/EEC12. The legislation is augmented by Annex 1 of European Commission (2006)
outlining necessary inputs for bTB eradication. Control tools include:
9 Commission Regulation (EC) No 1226/2002 of 8 July 2002 amending Annex B to Council Directive 64/432/EEC. OJ L 179,
9.7.2002, p. 13–18.
10 Council Directive 77/391/EEC of 17 May 1977 introducing Community measures for the eradication of brucellosis, tuberculosis
and leucosis in cattle. OJ L 145, 13.6.1977, p. 44–47.
11 Council Directive 82/400/EEC of 14 June 1982 amending Directive 77/391/EEC and introducing a supplementary Community
measure for the eradication of brucellosis, tuberculosis and leucosis in cattle. OJ L 173, 19.6.1982, p. 18–19.
12 87/58/EEC: Council Decision of 22 December 1986 introducing a supplementary Community measure for the eradication of
brucellosis, tuberculosis and leucosis in cattle. OJ L 24, 27.1.1987, p. 51–53.
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• Compulsory regular periodic testing of cattle at a risk-based testing frequency by intradermal
skin testing together with slaughter of reactor cattle and other cattle likely to have been
infected by contact.
• Strategic use of the IFN-c test.
• Prohibition of movements of cattle out of herds that are not OTF and in which infection is
suspected or conﬁrmed.
• Inspection of the carcasses of all cattle slaughtered for human consumption, with laboratory
testing of any lesions, from test negative cattle, suspected of being tuberculous.
• Import controls on live animals to reduce risk of importing infected animals.
• Pasteurisation of milk and milk products except for speciﬁc premises whose products are
subject to periodic monitoring and from OTF farms particularly in OTF counties.
• On farm biosecurity measures to reduce transmission of M. bovis between cattle, other
domestic livestock and wildlife.
• Disease should be addressed in all susceptible and infected species.
In principle, the risk-mitigating measures should be effective and proportionate; the disease has
been eradicated in several countries and the prevalence at EU level has decreased following
implementation of the speciﬁc legislation above and the so called ‘trading directive’ Council Directive
64/432/EEC as amended and the conditions laid down by the OIE and WHO. However, in some
settings, the risk-mitigating measures are neither effective nor proportionate, in particular, the
measures laid down in the legislation apply solely to bovine animals, but M. bovis is not a single host
pathogen. As a fundamental epidemiological principle, a disease which is shared and maintained
independently by a range of species in the same environment cannot be effectively controlled only by
addressing the problem in one of the affected species. If the control measures are not applied to all
epidemiologically relevant species - either farmed (goats, alpaca, deer, pigs, sheep) or wildlife (badger,
wild boar, deer) then eradication of tuberculosis in bovines will be highly improbable.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
Bulgaria, Croatia, Cyprus, Greece, Ireland, Italy, Portugal, Romania, Spain and the United Kingdom
did not achieve the country-level OTF status in 2015 (EFSA and ECDC, 2016).
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Production losses due to clinical disease are low in Europe due to statutory surveillance in affected
MSs. Economic loss is generally due to the implementation of the test and slaughter control strategies
and movement restrictions. Examples of such losses are given in Section 3.1.5.1 Parameter 1.
Production losses will vary, both between infected animals and infected herds. Studies have found that
bTB was associated with a 18% decrease in milk production in cattle in Bangladesh (Rahman and
Samad, 2008) and 4% in USA (Hernandez and Baca, 1998). Bovine tuberculosis has been reported to
decrease meat production by 6–12% ( 2.5%), depending on the percentage of cows (30–70%) in a
herd in which more than 80% of all animals or more than 95% of cows are infected (Zinsstag et al.,
2006).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Transmissibility between animals and humans
Parameter 1 – Types of routes of transmission between animals and humans
The routes of transmission of TB from animals to humans are well known and include direct
exposure to infected animals or consumption of contaminated animal products (Francis, 1948).
Application of ﬁngerprinting tools facilitates analysis of the molecular epidemiology of M. bovis in
animal-to-human and human-to-human transmission. Nevertheless, other members within the MTBC
can be zoonotic (Olea-Popelka et al., 2017). Improvements in diagnostic techniques, application of
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more advanced discriminatory genotyping tools, and collaboration between veterinary and human
health care researchers are key to our understanding of this zoonosis. Infected humans are a potential
risk for animals and other humans. All forms of TB may occur as a latent infection in many humans
and extra-pulmonary TB as a consequence of oral infection tends to have limited transmission
pathways in humans. When infection is pulmonary, the risk is not only to immunocompromised
individuals. The development of genotyping techniques has allowed the demonstration of person-
to-person transmission events involving M. bovis (Gibson et al., 2004). The few reports that have been
able to identify such events investigate clusters comprising a small number of cases with close
epidemiological relationships (Evans et al., 2007).
Parameter 2 – Incidence of zoonotic cases
The overall consumption risk in Europe is currently negligible because of wide scale milk
pasteurisation and compulsory regular screening of cattle by the tuberculin skin test in non-OTF
regions and inspection of carcasses at slaughter. Inhalation of the organism and risks of cutaneous
wounds in those dressing carcasses is signiﬁcant for people working with infected animals but is not
usually important for the general public.
In 2015, 170 conﬁrmed cases of tuberculosis due to M. bovis in humans were reported by 26 EU
MSs (EFSA and ECDC, 2016). However, this is probably an underestimate as media designed to culture
M. bovis is not always used as a routine. Eleven MSs reported at least one conﬁrmed case and 15 MSs
reported zero cases. The EU notiﬁcation rate was 0.03 cases per 100,000 population, the same as in
previous years. Most cases were reported in Germany, the United Kingdom and Spain, while the
highest notiﬁcation rate (0.11 cases per 100,000 population) was observed in Ireland.
Transmissibility between humans
Parameter 3 – Human to human transmission is sufﬁcient to sustain sporadic cases or community-level
outbreak
Infected humans are a potential risk for other humans especially when infection is pulmonary. In
2006, DNA investigation techniques showed that a cluster of 6 cases in the UK were linked by human
to human transmission (Evans et al., 2007). In a second reported outbreak, 19 cases in HIV-1-infected
patients of primary multidrug-resistant (MDR) tuberculosis were caused by M. bovis resistant to 11
antituberculosis drugs. Both phenotypic and genotypic similarities in the strains of M. bovis were
reported (Guerrero et al., 1997).
Parameter 4 – Sporadic, endemic, epidemic, or pandemic potential
There is a sporadic potential in humans.
The severity of human forms of the disease
Parameter 5 – Disability-adjusted life year (DALY)
In common with all causes of TB in humans, infection with M. bovis is potentially fatal, although
not everyone infected with the bacterium develops disease. The bacteria may remain inactive in the
body for many years and, in some individuals, reactivation occurs later. Once disease develops, about
half the patients will die within 5 years if untreated, the majority of these within the ﬁrst 18 months.
Treatment with a course of antituberculosis drugs usually results in cure. Infection by M. bovis is
thought to be clinically indistinguishable from infection with M. tuberculosis. However, discrimination
between M. bovis and M. tuberculosis is not routinely performed and reported in many countries (de la
Rua-Domenech, 2006). TB halts work in the formal and informal economies, as well as within
households. Country studies document between 3- and 4-month work time lost annually to the
disease, and lost earnings of 20–30% of household income. Families of persons who die from the
disease lose about 15 years of income. As economic difﬁculties put pressure on state health budgets,
the social cost of this lost productivity is compounded.
The availability of effective prevention or medical treatment in humans
Parameter 6 – Availability of medical treatment and their effectiveness (therapeutic effect and any
resistance)
M. bovis is naturally resistant to pyrazinamide, one of the four medications used in the standard
ﬁrst-line anti-tuberculosis treatment regimen. Thus, humans with M. bovis infection are treated with
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antimicrobial drugs including isoniazid, rifampicin and ethambutol. A long intensive course of treatment
is required (6–9 months).
Parameter 7 – Availability of vaccines and their effectiveness (reduced morbidity)
At present the only available vaccine for humans is Bacillus Calmette-Guerin (BCG), which is a live
attenuated strain of M. bovis. Reported efﬁcacy ranges from 0% to 80% (Fine, 1995).
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Infection with M. bovis can cause welfare issues once clinical signs are expressed, although farmed
animals in the EU are managed and therefore kept under observation; any clinical signs are likely to be
investigated and action taken before serious welfare issues arise. Therefore, the modal presentation in
cattle is a clinically inapparent infection disclosed as a result of routine TB testing. Some animals will
become diseased, with clinical signs such as coughing, difﬁculty in breathing, enlarged lymph nodes of
head and neck, intermittent diarrhoea, extreme emaciation, weakness and acute respiratory distress.
In addition, a drop in milk production may be observed in clinically affected high yielding dairy cows.
Even in chronically infected animals, characteristic signs of disease may not be readily apparent.
Although M. bovis affects a wide range of animal hosts, particularly mammals, there is wide
variation in levels of natural susceptibility and propensity to develop severe disease between species
(Francis, 1958; Une and Mori, 2007). However, all species, including those that usually develop mild
forms of disease, have the capacity to develop generalised or advanced tuberculosis. Such progressive
disease may typically be associated with emaciation, old age, concomitant infections and other factors
that may negatively impact on the immune system of the host. Wild animals with end stage
tuberculosis typically show emaciation, lethargy and abnormal behaviour (Wilson et al., 2009).
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
In the EU, Iberian Lynx, bear, European bison.
Parameter 2 – Mortality in wild species
EU wildlife species at risk – all mammals including badgers, red deer, roe deer, wild boar, feral pigs,
red fox, mink, ferret, Iberian lynx. Of this list, only the Iberian Lynx is endangered (Wilson et al.,
2009).
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
M. bovis can survive for some weeks in the environment. Dufﬁeld and Young (1985) report that
M. bovis survived for 4 weeks in non-sterile dry and moist soils held under 80% shade, in darkness
and in the laboratory. It was also isolated from sterile moist soil kept in the shade and in darkness.
Maintenance hosts include badger, deer and wild boar - level of mortality caused by M. bovis
infection is largely unknown. Models have been used to estimate differential survival, force of infection
and progression in disease states in a population of Eurasian badgers (Meles meles), naturally infected
with bTB. These state-dependent models found evidence for early onset of disease-induced mortality
in male but not female badgers. Males also had higher risk of infection and more rapid disease
progression (Graham et al., 2013).
A recent study of two different populations of wild boar with endemic TB in Spain suggested that
TB accounted for 30% of total deaths (Barasona et al., 2016).
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
Bovine TB is listed in the OIE list of notiﬁable terrestrial and aquatic animal diseases (http://www.
oie.int/animal-health-in-the-world/oie-listed-diseases-2017/), but not classiﬁed as potential bioterrorism
agent by CDC.
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Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
It is not listed.
Parameter 3 – Included in any other list of potential bio-agro-terrorism agents
It is not listed.
Infection with MTBC may have the potential to generate some conﬂict situations between different
stakeholders, like farmers, hunters and conservationists. This is due to the multihost system of MTBC,
which can generate a disease gradient between livestock and wildlife, leading to conﬂict between
different parties with different interests. In wild ungulates high MTBC prevalence has been recorded, in
a system where the livestock population is also involved. The presence of MTBC at the interface
between domestic animals and wildlife also generates conﬂict around protected areas (Gortazar et al.,
2010).
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
Council Directive 64/432/ECC recognises the in vivo SIT and SCIT, respectively, tests as the ofﬁcial
diagnostic assays for bovine TB in the Member States. To maximise detection of infected and diseased
cattle in a herd or in a region, MS may authorise the employ of the in vitro IFN-c referred in the OIE
Manual of Standards for Diagnostic Tests and Vaccines (OIE, 2015) as an ancillary assay to the
tuberculin test. The Bovigam® M. bovis gamma interferon test is OIE certiﬁed. Both in vivo and in vitro
assays are performed using puriﬁed protein derivatives (PPDs) obtained from the heat-treated
products of growth and lysis of M. bovis (bovine PPD) and M. avium (avian PPD) as described in
Annex B of the Directive. IDEXX serological test may be used as an ancillary test in infected herds. The
IDEXX test is OIE certiﬁed but not listed in the EU as a recognised test.
Tissues are taken from immune positive animals and conﬁrmation of infection is by bacterial
culture. Conﬁrmation through microscopic histological examination of PME material is also regularly
performed. PCR is becoming increasingly used because it allows a faster diagnosis than conventional
culture.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
Sensitivity and speciﬁcity estimates for diagnostic tests can be dependent upon the animal
population studied and the disease characteristics within the population. Caution should be exercised
in extrapolating sensitivity and speciﬁcity estimates made from populations of animals different from
those in which the test is being performed (Strain et al., 2011). Biological potency of the tuberculins is
critical for the outcome of the intradermal test and a signiﬁcant difference in the numbers of reactors
and infected bovines detected using high and low potency tuberculins has been reported (Good et al.,
2011).
A summary of the test performance characteristics can be found on the website of the European
Reference Laboratory for Bovine Tuberculosis (https://www.visavet.es/bovinetuberculosis/bovine-tb/dia
gnosis.php) and are given below.
Reported sensitivity of the SIT test in cattle ranged between 80.2% and 100% although it was
evaluated under speciﬁc epidemiological circumstances (de la Rua-Domenech, 2006). More recently
and using a Bayesian approach, the estimate sensitivity of the SIT test ranged between 53%
(27.3–81.5, 95% CI) and 69.4% (40.1–92.2, 95% CI) depending on the interpretation criteria used
(Alvarez et al., 2012a,b). The results from this study highlighted the low sensitivity of the intradermal
test after the disclosure test. Reported Sp of the SIT test ranged between 55.1% and more than 99%
showing a median value over 95% (de la Rua-Domenech et al., 2006; Schiller et al., 2010; Downs
et al., 2011; Alvarez et al., 2012a).
Sensitivity of the SCIT test is lower than that achieved using the SIT test. Reported values ranged
between 52% and 100% (de la Rua-Domenech et al., 2006; Duarte et al., 2008; Schiller et al., 2010).
In the presence of interference factors (e.g. infection by environmental mycobacteria), comparative
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interpretation increases the Sp (median of 99.5%) (de la Rua-Domenech et al., 2006; Schiller et al.,
2010).
Field studies carried out in the last two decades with the aim of comparing the diagnostic
performance of the tuberculin intradermal test and the IFN-c assay, demonstrated the higher
sensitivity of the IFN-c test. Nevertheless, the speciﬁcity achieved was similar or slightly lower than
that of the SIT, and lower than the Sp of the SCIT test. A meta-analysis of 15 ﬁeld studies conducted
between 1991 and 2006, showed an estimated median Se of 87.6% with a range between 73% and
100% and a Sp of 96.6% with a range of 85% and 99.6% for the IFN-c assay (de la Rua-Domenech
et al., 2006). The higher Se of the IFN-c test compared to the skin test is likely due to the fact that
the IFN-c test detects TB-infected animals as early as 14 days following infection (Buddle et al., 1995)
and 60–120 days earlier than the SCIT test (Lilenbaum et al., 1999). The EFSA Panel on Animal Health
and Welfare has published a comprehensive review of the data for the gamma interferon test and their
scientiﬁc opinion on the use of gamma interferon test for the diagnosis of bovine tuberculosis (EFSA
AHAW Panel, 2012).
The OIE accredited IDEXX serological test, recommended by OIE as the most suitable of the
antibody-detection tests which can be a complement, rather than an alternative, to tests based on
cellular immunity and helpful in detecting anergic cattle and deer has a reported Sp 97.4–98.8% and
herd sensitivity of 77.8%.
Culture is considered to be highly speciﬁc but the test procedure requires 6 weeks. Bayesian
models have been developed to compare PCR, bacteriology and histopathology, allowing for
dependence between bacteriology and PCR, while assuming independence from histopathology
(Courcoul et al., 2014). The sensitivity of PCR was higher than that of bacteriology (on average 87.7%
[82.5–92.3%] vs 78.1% [72.9–82.8%]) while speciﬁcity of both tests was very good (on average
97.0% for PCR [94.3–99.0%] and 99.1% for bacteriology [97.1–100.0%]). Histopathology was at least
as sensitive as PCR (on average 93.6% [89.9–96.9%]) but less speciﬁc than the two other tests (on
average 83.3% [78.7–87.6%]).
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
Blood (IFN-c, serology), milk, urine, faeces, biopsy, post mortem examination of tissues.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
Vaccination of cattle against bovine tuberculosis is explicitly forbidden in the EU legislation on
disease control (Council Directive 78/52/EEC13) and implicitly also in intra-Union trade legislation, as
vaccination is not compatible with the provisions for testing and herd qualiﬁcation (Council Directive
64/432/EEC). EU legislation is fully in line with OIE standards on international trade and can be
changed only by the European Parliament and the Council. Recently, the EFSA AHAW Panel published
a scientiﬁc opinion on the requirements for ﬁeld trials for bovine tuberculosis vaccination (EFSA AHAW
Panel, 2013).
A live attenuated vaccine BadgerBCG vaccine has been granted a unique Limited Marketing
Authorisation (LMA) for use in badgers only in the UK.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
Vaccination with BCG has been shown to reduce the severity and progression of experimentally
induced TB in captive badgers. Analysis of data from a 4-year clinical ﬁeld study, conducted at the
social group level, suggested a similar, direct protective effect of BCG in a wild badger population and
both a direct beneﬁcial effect of vaccination in individual badgers and an indirect protective effect in
unvaccinated cubs. Intramuscular injection of BCG reduced by 54% (odds ratio = 0.46, 95% CI
0.26–0.88) the risk of free-living vaccinated individuals testing positive to a diagnostic test combination
13 Council Directive 78/52/EEC of 13 December 1977 establishing the Community criteria for national plans for the accelerated
eradication of brucellosis, tuberculosis and enzootic leukosis in cattle. OJ L 15, 19.1.1978, p. 34–41.
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to detect M. bovis infection following vaccination. In addition, the risk of unvaccinated badger cubs,
but not adults, testing positive decreased signiﬁcantly as the proportion of vaccinated individuals in
their social group increased (Odds ratio = 0.08, 95% CI 0.01–0.76; p = 0.03). When more than a third
of their social group had been vaccinated, the risk to unvaccinated cubs was reduced by 79% (Odds
ratio = 0.21, 95% CI 0.05–0.81; p = 0.02) (Chambers et al., 2011; Carter et al., 2012).
The results of an oral BCG vaccination ﬁeld trial conducted in Ireland on wild free-living badgers
has also recently been published which has established that oral vaccination of free-living badgers can
reduce the incidence of tuberculosis in free-ranging badger populations (Gormley et al., 2017).
Parameter 4 – Duration of protection
Duration of immunity for BadgerBCG is currently unknown but annual vaccination is recommended.
Feasibility
Parameter 5 – Way of administration
BadgerBCG has a limited licence in the UK only for intramuscular injection. Trapping of animals is
required to carry out this procedure (Brown et al., 2013).
3.1.4.3. Article 7(d)(iii) Medical treatments
The mycobacteria are susceptible to antibiotics, although M. bovis is intrinsically resistant to
pyrazinamide. Humans infected with M. bovis are treated with antimicrobial drugs including isoniazid,
rifampicin and ethambutol. A long intensive course of treatment (6–9 months) is required. Infected
animals are generally slaughtered and are not treated except where the value of the animal is great,
e.g. zoo animals or domestic pets.
Antibiotic therapy of bovine tuberculosis is not recommended.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
• RESTRICT contact between wildlife and cattle.
• MANAGE cattle feed and water.
• STOP infected cattle entering the herd.
• REDUCE risk from neighbouring herds.
• MINIMISE infection from cattle manure.
The evidence-base behind these measures can be found at http://www.tbhub.co.uk/biosecurity/
protect-herd-tb-review-science/
In addition risk of infection can be reduced by reducing the population of other infected species
(farmed or wild) that share the same environment.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
The relative importance of various routes of transmission is poorly known and no quantitative
estimates of any of these transmission rates are available. Thus, a strong evidence base to evaluate
different strategies is currently lacking (Godfray et al., 2013).
Feasibility
Parameter 3 – Feasibility of biosecurity measures
This will vary from farm to farm and will depend upon the most important risk factors for
transmission of M. bovis to livestock on the farm.
TB eradication has been achieved by a number of MSs using a test and slaughter control
programme laid down by Council Directive 64/432/EEC that includes prohibition of movements of
animals from infected herds.
There is a lack of a strong evidence base with which to assess the feasibility of biosecurity
measures (Godfray et al., 2013). Simple exclusion measures have been reported to be 100% effective
in preventing badger entry into farm buildings, as long as they were appropriately deployed. The
installation of exclusion measures also reduced the level of badger visits to the rest of the farmyard
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thereby reducing some of the potential for contact and disease transmission between badgers and
cattle (Judge et al., 2011). No effective measures to prevent badgers utilising cattle pasture for forage
have been reported and such practices could conceivably have a negative welfare impact on badgers
by limiting food source/supply. However, other studies have demonstrated that there is little direct
contact between badgers and cattle and also that badgers do not regularly frequent farm
yards/buildings. In such circumstances, biosecurity measures preventing badger ingress to farm
buildings are unlikely to have an effect in reducing bTB risk in cograzing cattle (Mullen et al., 2013;
O’Mahony, 2014; Mullen et al., 2015; O’Mahony, 2015a,b). There is also evidence of cattle exposure to
environmental contamination from wildlife sources (King et al., 2015; Barbier et al., 2016).
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
These are laid out in Council Directive 64/432/EEC. Detection of positive animals results in
restrictions on the movement of cattle from the herd: only reactor animals going directly to slaughter
can be removed and farmers receive compensation for reactor animals. Movement restrictions are only
lifted after a minimum of two clear tests, the second of which must be carried out a minimum of
4 months from the date of removal of the last positive animal and only once the premises have been
cleaned and disinfected.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
TB eradication has been achieved by a number of MSs using a test and slaughter control
programme laid down by Council Directive 64/432/EEC that includes prohibition of movements of
animals from infected herds.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
This is a requirement of any TB control programme in Europe (Council Directive 64/432/ECC).
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animal
• Compulsory slaughter of cattle that react to the skin test at licensed abattoirs.
• Culling of wildlife reservoirs.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
The test and slaughter programme for the control of bTB in cattle is laid down in Council Directive
64/432/EEC and has proved effective at eradicating bovine tuberculosis from many MSs in Europe.
However, the strategy has proved less successful in MSs with wildlife reservoirs of M. bovis or
M. caprae.
In Europe, widespread indiscriminate culling of the important wildlife hosts of bovine tuberculosis is
unlikely to offer an effective solution on its own. However, targeted culling may have a role under
certain circumstances (Grifﬁn et al., 2005; Donnelly et al., 2007) especially if employed together with
other measures such as vaccination and improved biosecurity of domestic animals alongside cattle
testing and controls. The potential for targeted culling to be used successfully may be enhanced as a
result of on-going developments in diagnostic testing and improved understanding of bTB dynamics in
wildlife (Wilson et al., 2009; Smith et al., 2012; Gortazar et al., 2015; Abdou et al., 2016).
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Feasibility
Parameter 3 – Feasibility of killing animals
Livestock are regularly disposed of using well-established methodologies in licensed abattoirs as
required by Council Directive 64/432/EEC.
For wildlife, a number of factors must be carefully considered in order to determine if culling is
appropriate. Resource availability, the size of the infected area, the ecology of the wildlife host, and
the period over which culling is required will all inﬂuence whether this is a cost-effective approach.
Culling can have both positive and potentially negative and sometimes unpredictable consequences.
Culled populations may respond by increasing productivity, so that culling may have to be repeated at
regular intervals, with cost and logistical implications. Such compensatory reproduction may also have
counterproductive effects such as increasing the proportion of young, susceptible individuals in the
population. Culling may also promote increased dispersal by surviving animals, and increased
immigration into the culled area (Wilson et al., 2009; Gortazar et al., 2015).
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
Regulation (EC) No 1069/200914 lays down animal and public health rules for animal by-products
and products derived thereof. It determines the circumstances under which animal by-products are to
be disposed of, in order to prevent the spreading of risks for public and animal health. In addition, that
Regulation speciﬁes under which conditions animal by-products may be used for applications in animal
feed and for various purposes, such as in cosmetics, medicinal products and technical applications. It
also lays down obligations for operators to handle animal by-products within establishments and plants
that are subject to ofﬁcial controls. Positive animals are normally slaughtered in licensed
slaughterhouses, but are kept separate from other cattle. The carcasses are then inspected for ‘MTBC
lesions’ and samples are sent to a diagnostic laboratory.
Regulation (EC) No 1069/2009 requires, among other things, that wild animals suspected of being
infected with diseases communicable to humans and animals, such as tuberculosis, are disposed of at
an approved plant using one of the following methods: (1) incineration; (2) rendering followed by
incineration; or (3) pressure rendering followed by landﬁll. In addition, the regulation also allows for
burial and burning of dead animals in speciﬁc situations.
Effectiveness
Parameter 2 – Effectiveness of disposal option
Incineration and rendering are closed systems that produce an effective inactivation of M. bovis.
Feasibility
Parameter 3 – Feasibility of disposal option
Livestock are regularly disposed of by the methods described. Strict biosecurity during carcass
transport is also required.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
This is very difﬁcult to quantify since it depends on the size of the premise, type of production and
OTF status of the MS. Figures are available for two of the MSs with the highest prevalence of bovine
tuberculosis.
14 Regulation (EC) No 1069/2009 of the European Parliament and of the Council of 21 October 2009 laying down health rules as
regards animal by-products and derived products not intended for human consumption and repealing Regulation (EC)
No 1774/2002 (Animal by-products Regulation). OJ L 300, 14.11.2009, p. 1–33.
AHL assessment on bovine tuberculosis
www.efsa.europa.eu/efsajournal 23 EFSA Journal 2017;15(8):4959
UK Government expenditure on bTB control (including testing, compensation and research) in GB
during 2010/2011 was over £100 million. The estimated cost of a conﬁrmed herd breakdown in areas
of high risk for bovine tuberculosis in England was £14,000 to farmers and £20,000 to government.
Bovine tuberculosis control in Ireland costs approximately €80 million annually: €50 million from
government and € 30 million from producers (Duignan et al., 2012).
Parameter 2 – Cost of eradication (culling, compensation)
Over the period of 2005–2011, 15.5% of EU co-funding covered the eradication of bTB. Across
Europe, €62 million has been allocated to support eradication, control and surveillance programmes
that aim to eliminate bTB in 2016.
Between 2007 and 2011, the total cost incurred by the Health Service of Lazio Region (Italy) for
the eradication of bTB was estimated in 6 788 294 EUR, of those about 6 million were the cost of the
veterinarians labour, 35,454 for the transport, 234,314 for disposal and compensation for culled
animals (Caminiti et al., 2016).
The expected overall cost of national veterinary programme for the eradication of bTB submitted for
obtaining EU co-ﬁnancing from non-OTF MSs to European Commission in 2015 and 2016 is reported in
Table 1 (https://ec.europa.eu/food/funding/animal-health/national-veterinary-programmes_en).
Parameter 3 – Cost of surveillance and monitoring
UK Spend for surveillance in GB was approximately £64 million for 2010/2011.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
Assurances on tuberculosis free status are required for EU trade in bovine animals and products.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
There has been no published systematic assessment of this. It will vary from MS to MS.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
Disease prevention and control methods for bTB in cattle as laid down by Council Directive 64/432/EEC
is well accepted across MSs in Europe.
Disease control measures for wildlife are more contentious and societal acceptance is likely to vary
according to MS and to different stakeholders within MSs (Carstensen et al., 2011; Gross, 2013; Cowie
et al., 2015; More and Good, 2015).
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
The OIE developed international standards to provide advice on humane killing for various species
and situations (OIE, 2012). In the situation of emergency killing for diseases control purposes,
preventing or minimising risks to human health and safety often take priority over animal welfare
Table 1: Total expected amount of the cost of the eradication programme for bovine tuberculosis in
some non-OTF MSs in 2015 and 2016 (https://ec.europa.eu/food/funding/animal-health/na
tional-veterinary-programmes_en)
Member State Total expected cost in € in 2015 Total expected cost in € in 2016
Austria 542,309 213,339
Croatia 3,008,980 –
Ireland 62,320,389 62,881,246
Italy 10,954,624 10,700,583
Portugal 3,222,491 1,998,849
Spain 43,130,259 29,899,297
UK 74,868,739 107,354,817
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concerns. Council Regulation (EC) No 1099/200915 lays down rules for the killing of animals at
slaughter and in case of emergency killing outside of a slaughterhouse. The Regulation provides for
appropriate planning, supervision and reporting of emergency killing cases. The use of killing methods
that pose risks to animal welfare is not allowed except under exceptional circumstances (e.g. risks
posed to human health or uncontainable animal diseases). The application of humane slaughterhouse
practices has recently been reviewed (Gavinelli et al., 2014; Thornber et al., 2014).
Parameter 2 – Wildlife depopulation as a control measure
Wild boar, deer and badgers are hunted species in most parts of the EU, so welfare is unlikely to be
a major issue for these species.
Badger culling has been carried out in at least two MSs as part of a TB eradication strategy. Until
recently, these both required animals to be trapped. The two main trapping methods have been
stopped cable restraints and cage traps (Woodroffe et al., 2005b; Murphy et al., 2009). Both methods
result in low prevalence of serious injury (Woodroffe et al., 2005a; Murphy et al., 2009). However,
both trapping methods could cause other welfare concerns related to stress or environmental exposure
(Talling and Inglis, 2009; Sharp and Saunders, 2011). A practical adaptive management system has
been proposed by Bryne et al. (2015) to monitor trap-related injuries as a component of broader
attempts to maintain welfare standards.
Recently, free-shooting of non-trapped badgers has been trialled in GB. An Independent Expert
Panel report on these pilot trials found that 7.4–22.8% (95% CI) of badgers were still alive after
5 min, i.e. that the Panel were 95% conﬁdent that the number of badgers estimated as taking more
than 5 min to die exceeded 5%. Consequently, the Panel recommended that to improve standards of
humaneness, only shooters who have demonstrated a high standard of marksmanship in the ﬁeld, and
who have a good knowledge of badger behaviour, should be licensed (Munro, 2014).
Data suggest that a closed season is effective in reducing the suffering of unweaned cubs in
badger populations subject to culling (Woodroffe et al., 2005a).
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Manufacture and use of disinfectants in the EU must comply with Regulation (EU) No 528/201216.
Biodiversity
Parameter 2 – Mortality in wild species
It is difﬁcult to assess mortality due to M. bovis infection in wildlife populations. However, as above,
the following estimations have been reported.
Badgers: There is evidence for early onset of disease-induced mortality in male but not female
badgers. In a long-term study of a natural population of badgers to the nearest month, male average
life expectancies were estimated to be 32 months for uninfected badgers and 22 months for infected
badgers. Female average life expectancies were found to be 40 months for uninfected badgers and
35 months for infected badgers (McDonald et al., 2014).
Wild boar: A recent study of two different populations of wild boar with endemic tuberculosis in
Spain suggested that tuberculosis accounted for 30% of total deaths (Barasona et al., 2016).
In a randomised badger culling trial in GB, culling of badgers led to an associated increase in
populations of red foxes and hedgehogs. In both cases, the responses were highly variable amongst
areas and are likely to be mediated by other complex ecological interactions (Trewby et al., 2008,
2014).
15 Council Regulation (EC) No 1099/2009 of 24 September 2009 on the protection of animals at the time of killing. OJ L 303,
18.11.2009, p. 1–30.
16 Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available
on the market and use of biocidal products. OJ L 167, 27.6.2012, p. 1–123.
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3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about bTB (Table 2). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 11. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 3, 4 and 5). The proportion of Y, N or na answers are reported,
followed by the list of different supporting views for each answer.
Table 2: Outcome of the expert judgement on the Article 5 criteria for bovine tuberculosis
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist in
the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal health,
or poses or could pose a signiﬁcant risk to public health due to its zoonotic character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger to
public and/or animal health in the Union
NC
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for the
purpose of bioterrorism
NC
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
NC
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 3: Outcome of the expert judgement related to criterion 5 B(ii)
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
B(ii) The disease agent has developed resistance to treatments and poses a
signiﬁcant danger to public and/or animal health in the Union
NC 9 91 0
NC: non-consensus; number of judges: 11.
AHL assessment on bovine tuberculosis
www.efsa.europa.eu/efsajournal 26 EFSA Journal 2017;15(8):4959
Reasoning supporting the judgement
Supporting Yes:
• General treatment of animals with antibiotics for concurrent infections may lead, inadvertently,
to antibiotic resistant strains of M. bovis.
• Antimicrobial resistance in humans has been observed for all bacteria belonging to MTBC, which
includes M. bovis. However, M. bovis in humans is underdiagnosed and no differentiation
among strains is carried out, so M. bovis is treated more often than realised and the treatment
will include the antimicrobials to which M. bovis is naturally resistant; it could survive longer and
that increases the likelihood of resistance to the other antimicrobials in the suite developing.
Supporting No:
• There are few cases of antimicrobial resistance of M. bovis in humans, but this is not signiﬁcantly
important for public health as these strains were not related to infections in animals. Moreover,
infection in animals is not treated with antimicrobials, and all infected animals are killed.
• M. bovis has been found naturally resistant to pyrazinamide, although currently other resistant
strains are infrequent.
Reasoning supporting the judgement
Supporting Yes:
• If the disease was uncontrolled, there is the potential for massive spread of infection, with raw
meat or raw milk posing a potential threat to public health. This may lead to a loss of
conﬁdence in consumers (similar to the crisis due to BSE). Moreover, if left uncontrolled,
slaughtering of ﬂocks would be applied to control the disease, and this may generate an
impact on the public opinion.
• The disease, since it can affect multiple host species, both domestic and wild, that often share
the same environment, can currently lead to critical situations due to the conﬂict between
farmers, hunters and authorities.
Supporting No:
• The disease is not listed as a bio- or agro-terrorism agent.
• The disease has a slow natural evolution in the host population, and therefore, it seems
unlikely to be used for bioterrorism purposes.
• A crisis between hunters and breeders would not be signiﬁcantly relevant for the whole society.
• Contamination of food can be prevented by pasteurisation and recall of contaminated milk
would not cause a crisis at national level.
• It would be of concern if new outbreak(s) occur(s) in a previously free area. However, due to
the slow spread of the disease and the efﬁcacy of mitigation measures, there is a very low
probability of generating a crisis.
Table 4: Outcome of the expert judgement related to criterion 5 B(iv)
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
B(iv) The disease has the potential to generate a crisis or the disease
agent could be used for the purpose of bioterrorism
NC 27 73 0
NC: non-consensus; number of judges: 11.
Table 5: Outcome of the expert judgement related to criterion 5 B(v)
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
B(v) The disease has or could have a signiﬁcant negative impact on
the environment, including biodiversity, of the Union
NC 91 9 0
NC: non-consensus; number of judges: 11.
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Reasoning supporting the judgement
Supporting Yes:
• The disease seriously affects endangered wild species such as Iberian lynx, bear, and bison;
the presence of the disease in national parks raises conservation concerns.
• In Africa, the disease causes deaths in carnivores, contributing to the endangered status of
several wild species.
Supporting No:
• Considering the difﬁculties in assessing the effect of a disease on the ecosystem as a whole, if
only one endangered species is affected (Iberian lynx), biodiversity will not be reduced, except
in very small meta-population.
3.2.2. Outcome of the assessment of bovine tuberculosis according to criteria of
Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 2, bovine
tuberculosis complies with all criteria of the ﬁrst set and two criteria of the second set, therefore it is
considered eligible to be listed as laid down in Article 5 of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about bovine tuberculosis (Tables 6, 7, 8, 9 and 10). The expert
judgement was based on ICBA approach described in detail in the opinion on the methodology.
Experts have been provided with information of the disease fact-sheet mapped into Article 9 criteria
(see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement
on each criterion of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 8. The expert judgement was conducted as
described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation of
the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 6: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for bovine tuberculosis (CI = current impact; PI = potential
impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory of
the Union
N
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
At least one criterion to be met by the disease:
In addition to the criteria set out above at point 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
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5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
Y
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
Y
Colour code: green = consensus (Yes/No).
Table 7: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for bovine tuberculosis (CI = current impact; PI = potential
impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are free of
the disease
Y
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at point 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
Y
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5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
Y
Colour code: green = consensus (Yes/No).
Table 8: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for bovine tuberculosis (CI = current impact; PI = potential
impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
Y
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at point 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
Y
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
Y
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
Y
Colour code: green = consensus (Yes/No).
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3.3.1. Outcome of the assessment of criteria in Annex IV for bovine tuberculosis
for the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 6–10. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to the different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for bTB for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 11.
Table 9: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for bovine tuberculosis
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
the disease fulﬁls criteria of Section 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 10: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for bovine tuberculosis
Diseases in category E need to fulﬁl criteria of Section 1, 2 or 3 of Annex IV of AHL and/or
the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment (If a disease fulﬁls the criteria as in
Article 5, thus being eligible to be listed, consequently category E would apply.)
Y
Colour code: green = consensus (Yes/No).
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According to the assessment here performed, bTB complies with the following criteria of the
Sections 1 to 5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment bTB complies with criteria 2.2 and 2.3, but
not with criteria 1, 2.1 and 2.4. To be eligible for category A, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and bTB complies with
criteria 4, 5b, 5c and 5d, but not with criteria 3 and 5a.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment bTB complies with all of them. To be eligible
for category B, a disease needs to comply additionally with one of the criteria of the second
set (3, 4, 5a–d) and bTB complies with criteria 4, 5b, 5c and 5d, but not with criteria 3 and
5a.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment bTB complies with all of them. To be eligible for
category C, a disease needs to comply additionally with one of the criteria of the second set
(3, 4, 5a–d) and bTB complies with criteria 3, 4, 5b, 5c and 5d, but not with criterion 5a.
4) To be assigned to category D, a disease needs to comply with criteria of Section 1, 2, 3 or 5
of Annex IV of the AHL, with which bTB complies.
5) To be assigned to category E, a disease needs to comply with criteria of Section 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which bTB
complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
bTB. The Article 8(3) criteria are about animal species to be listed, as it reads below:
Table 11: Outcome of the assessment of criteria in Annex IV for bovine tuberculosis for the
purpose of categorisation as in Article 9 of the AHL (CI = current impact; PI = potential
impact)
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that
such role is likely’.
For this reason the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.17 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for bTB according to the criteria of
Article 8(3) of the AHL are as displayed in Table 12.
Table 12: Main animal species to be listed for bovine tuberculosis according to criteria of Article 8
(source: data reported in Section 3.1.1.1)
Class Order Family Genus/Species
Susceptible* Mammalia Artiodactyla Bovidae Bos spp., Bubalus spp., Syncerus spp., Bison
spp., Capra spp., antelopes, Tragelaphus
spp., Taurotragus spp., Oryx spp., Addax
spp., Ovis spp.
Cervidae Cervus elaphus, Capreolus capreolus, Dama
dama, Cervus canadensis
Suidae Sus spp.
Camelidae Camelus spp., Lama glama, Vicugna pacos
Carnivora Mustelidae Badgers (not speciﬁed), Neovison spp.,
Mustela spp., Mustela putorius furo, Lutra
spp.
Canidae Vulpes vulpes, Canis latrans, Canis lupus
familiaris
Felidae Lynx spp., Panthera leo, Panthera tigris,
Panthera pardus, Felis catus
Procyonidae Procyon lotor
seals (different
families)
Not speciﬁed
Rodentia Muridae Rattus spp.
Cricetidae Microtus agrestis
Sciuridae Squirrels
Eulipotyphla Talpidae Not speciﬁed
Primates not speciﬁed Not speciﬁed
Perissodactyla Tapiridae Not speciﬁed
Rhinocerotoidea Not speciﬁed
Equidae+ Not speciﬁed
Proboscidea Elephantidae Not speciﬁed
Didelphimorphia Didelphidae Not speciﬁed
Lagomorpha Leporidae Lepus spp., rabbits
Aves Columbiformes Columbidae Not speciﬁed
17 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to
new hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains
infected for shorter time than in biological vectors.
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4. Conclusions
TOR 1: for each of those seven diseases an assessment, following the criteria laid down in
Article 7 of the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3)
of the AHL;
• According to the assessment here performed, bTB complies with all criteria of the ﬁrst set and
with two criteria of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the seven diseases which was found eligible to be listed for Union
intervention, an assessment of its compliance with each of the criteria in Annex IV to the AHL for the
purpose of categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, bTB meets the criteria as in Sections 2, 3, 4 and
5 of Annex IV of the AHL, for the application of the disease prevention and control rules
referred to in points (b), (c), (d) and (e) of Article 9(1) of the AHL.
TOR 2b: for each of the seven diseases which was found eligible to be listed for Union
intervention, a list of animal species that should be considered candidates for listing in accordance with
Article 8 of the AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for bTB according to Article 8(3) of the AHL are several mammals as susceptible and
several species of Artiodactyla and Carnivora as reservoirs, as reported in Table 12 in
Section 3.4 of the present document.
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